Entactogen research targets social anxiety and isolation across diagnoses, pairing “plasticity windows” with psychotherapy amid shifting FDA scrutiny and evolving trial designs.
James Murrough, MD, PhD
Advertisement
Dr Murrough is a professor of psychiatry and neuroscience, and director of the Depression and Anxiety Center for Discovery and Treatment at the Icahn School of Medicine at Mount Sinai. He is also a faculty member of the Friedman Brain Institute and a primary principal investigator of the Center of Excellence in Neuropharmacology, both components of the Icahn School of Medicine.
Articles by James Murrough, MD, PhD
A relationship between inflammatory skin disease and depression revealed in new research.
This special collection provides new insights on major aspects of depression: psychopharmacology, therapeutic interventions, major depressive episodes, biomarkers, and pseudobulbar affect.
Despite the scope and magnitude of rising rates of depression and suicide, the field of psychiatry may be witnessing a turning point.
Advertisement
Latest Updated Articles
5 Reports on DepressionAugust 10th 2018
Advertisement
Advertisement
Trending on Psychiatric Times
1
Kratom Component in Clinical Trial for Opioid Use Disorder
2
Why Cultural Context Matters in Psychiatric Assessment
3
FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder
4
NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder
5